InvestorsHub Logo
Followers 53
Posts 1776
Boards Moderated 0
Alias Born 03/22/2015

Re: Dr Speculator Ninja post# 342226

Wednesday, 08/19/2020 8:36:57 AM

Wednesday, August 19, 2020 8:36:57 AM

Post# of 401679

This is why Nasrat was smart to switch strategies. We’re lucky to have him at the helm. Pressure is building, won’t stay at these levels much longer. Significant revenue increases can’t be ignored by the street.

https://www.reuters.com/article/us-purdue-pharma-investigations-opioids/u-s-states-seek-2-2-trillion-from-oxycontin-maker-purdue-pharma-filings-idUSKCN25D2EG





1. Comparing Elite with Purdue is delusional for any number of reasons. Nobody really believes there is any rational comparison between the business practices of these two companies. Purdue's behavior is not a legal risk for Elite. Elite manufactured and sold generic opioids since 2010 without any legal interference ever.

2. There is zero evidence of any "pressure" building in the stock price, which is a direct result of over 1 billion shares outstanding.

3. "Significant revenue increases" will require additional ANDA approvals. The Concerta application is not imminent and FDA approval before CY2022 is extremely unlikely.



Occam's razor: the simplest solution is most likely the right one.

Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News